- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT07683793
A Study to Compare How CHF10196 (Florensocatib) is Absorbed Into the Blood When Given Alone and With a Drug That Reduces Stomach Acid in Healthy Male Participants
An Open-label, Fixed-sequence, Non-randomised, Drug-drug Interaction Study to Evaluate the Effect of Pantoprazole (Proton Pump Inhibitor) on the Pharmacokinetics of CHF10196 in Healthy Male Participants.
Обзор исследования
Статус
Условия
Вмешательство/лечение
Тип исследования
Регистрация (Оцененный)
Фаза
- Фаза 1
Контакты и местонахождение
Контакты исследования
- Имя: Chiesi Clinical trial Info
- Номер телефона: +390521279715
- Электронная почта: clinicaltrials_info@chiesi.com
Места учебы
-
-
-
Leeds, Соединенное Королевство
- Fortrea Clinical Research Unit (CRU) Limited
-
Контакт:
- Firas Almezedi
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
- Взрослый
Принимает здоровых добровольцев
Описание
Key Inclusion Criteria:
- BMI (body mass index) between 18.0 and 30.0 kg/m²
- Weight between 45 and 100 kg
- Non-smokers or ex-smokers (<5 pack-years)
- Clinically healthy based on medical history and examination
- Normal vital signs
- Normal ECG
- Willingness to comply with contraception requirements
Key Exclusion Criteria:
- Recent participation in another clinical study
- Significant medical conditions
- Abnormal laboratory values
- Positive HIV or hepatitis tests
- Recent infection or COVID-19
- Drug or alcohol abuse
- Use of prohibited medications
- Gastrointestinal surgery affecting absorption
- Hypersensitivity to study drugs
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Н/Д
- Интервенционная модель: Последовательное назначение
- Маскировка: Нет (открытая этикетка)
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Экспериментальный: Fixed Sequence Treatment
CHF10196 - Pantoprazole - Pantoprazole with CHF10196
|
Treatment Period 1: CHF10196 single dose administration on Day1; Treatment Period 2: CHF10196 single dose administration after pantoprazole single dose administration on Day13 Treatment Period 2: Pantoprazole single dose administration from Day8 to Day13 |
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
PK parameter: AUC0-∞
Временное ограничение: pre-dose up to 168 hours post-dose
|
comparing the ratio of adjusted geometric means for area under the concentration time curve from time 0 extrapolated to infinity (AUC0-∞) when CHF10196 administered alone and when administered with pantoprazole
|
pre-dose up to 168 hours post-dose
|
|
PK parameter: AUC0-t
Временное ограничение: pre-dose up to 168 hours post-dose
|
comparing the ratio of adjusted geometric means for area under the plasma concentration time curve from time 0 to last quantifiable concentration (AUC0-t) when CHF10196 administered alone and when administered with pantoprazole
|
pre-dose up to 168 hours post-dose
|
|
PK parameter: Cmax
Временное ограничение: pre-dose up to 168 hours post-dose
|
comparing the ratio of adjusted geometric means for maximum observed concentration when CHF10196 administered alone and when administered with pantoprazole
|
pre-dose up to 168 hours post-dose
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Safety and tolerability: Incidence of adverse events (AE)
Временное ограничение: From baseline (Day -1) to Day 8 for treatment period 1; from Day 8 to Day 20 for treatment period 2
|
Number and percentage of adverse events (AE) when CHF10196 administered alone and when administered with pantoprazole
|
From baseline (Day -1) to Day 8 for treatment period 1; from Day 8 to Day 20 for treatment period 2
|
|
Safety and tolerability: Change from baselines for vital signs: PR
Временное ограничение: Day 1 to Day 7 for treatment period 1 and Day 8 to Day 19 for treatment period 2
|
Mean changes from baselines to each post-dose timepoint in PR (pulse rate), by treatment period (TP). Baselines (the last value before the first administration of any CHF10196 of each TP or pantoprazole (TP2 only). In TP2, two separate baselines will be derived relative to pantoprazole and CHF10196) |
Day 1 to Day 7 for treatment period 1 and Day 8 to Day 19 for treatment period 2
|
|
Safety and tolerability: Change from baselines for vital signs - RR
Временное ограничение: Day 1 to Day 7 for treatment period 1 and Day 8 to Day 19 for treatment period 2
|
Mean changes from baselines to each post-dose timepoint in vital signs: RR (respiratory rate) by treatment period (TP). Baselines (the last value before the first administration of any CHF10196 of each TP or pantoprazole (TP2 only). In TP2, two separate baselines will be derived relative to pantoprazole and CHF10196) |
Day 1 to Day 7 for treatment period 1 and Day 8 to Day 19 for treatment period 2
|
|
Safety and tolerability: Change from baselines for vital signs - blood pressure
Временное ограничение: Day 1 to Day 7 for treatment period 1 and Day 8 to Day 19 for treatment period 2
|
Mean changes from baselines to each post-dose timepoint in vital signs (Systolic Blood Pressure and Diastolic Blood Pressure) by treatment period (TP). Baselines (the last value before the first administration of any CHF10196 of each TP or pantoprazole (TP2 only). In TP2, two separate baselines will be derived relative to pantoprazole and CHF10196) |
Day 1 to Day 7 for treatment period 1 and Day 8 to Day 19 for treatment period 2
|
|
Safety and tolerability: Change from baselines for ECG
Временное ограничение: Day 1 to Day 7 for treatment period 1 and Day 8 to Day 19 for treatment period 2
|
change from baselines in milliseconds (ms). Intervals recorded: PR , RR, QT, QTc, QRS duration, QTcF (Fridericia-corrected QT interval Baselines (the last value before the first administration of any CHF10196 of each treatment period (TP) or pantoprazole (TP2 only). In TP2, two separate baselines will be derived relative to pantoprazole and CHF10196 |
Day 1 to Day 7 for treatment period 1 and Day 8 to Day 19 for treatment period 2
|
|
Safety and tolerability: Change from baseline for ECG (HR)
Временное ограничение: Day 1 to Day 7 for treatment period 1 and Day 8 to Day 19 for treatment period 2
|
change from baseline for ECG recording of heart rate (HR) Baselines (the last value before the first administration of any CHF10196 of each Treatment Period (TP) or pantoprazole (TP2 only). In TP2, two separate baselines will be derived relative to pantoprazole and CHF10196). |
Day 1 to Day 7 for treatment period 1 and Day 8 to Day 19 for treatment period 2
|
|
Safety and tolerability: Change from baseline for laboratory abnormalities
Временное ограничение: From baseline (Day -1) to Day 8 for treatment period 1; from Day 8 to Day 20 for treatment period 2
|
Number of participants with abnormal blood laboratory test results.
Quantitative laboratory parameters (chemistry and haematology) will be summarised by treatment as absolute value and change from baseline using descriptive statistics
|
From baseline (Day -1) to Day 8 for treatment period 1; from Day 8 to Day 20 for treatment period 2
|
|
Additional pharmacokinetic parameters: AUC0-24h
Временное ограничение: From Day 1 to Day 2 for treatment period 1; from Day 13 to Day 14 for treatment period 2
|
comparing the ratio of adjusted geometric means for the area under the plasma concentration time curve from time 0 to 24 h post-dose when CHF10196 administered alone and when administered with pantoprazole (with their 90% two-sided Confidence Intervals)
|
From Day 1 to Day 2 for treatment period 1; from Day 13 to Day 14 for treatment period 2
|
|
Additional pharmacokinetic parameters: CL/F
Временное ограничение: From baseline (Day -1) to Day 8 for treatment period 1; from Day 8 to Day 20 for treatment period 2
|
comparing the total body clearance (CL/F) by treatment period using descriptive statistics
|
From baseline (Day -1) to Day 8 for treatment period 1; from Day 8 to Day 20 for treatment period 2
|
|
Additional pharmacokinetic parameters: t1/2
Временное ограничение: From baseline (Day -1) to Day 8 for treatment period 1; from Day 8 to Day 20 for treatment period 2
|
comparing the terminal half-life (t1/2) by treatment period using descriptive statistics
|
From baseline (Day -1) to Day 8 for treatment period 1; from Day 8 to Day 20 for treatment period 2
|
|
Additional pharmacokinetic parameters: Vd/F
Временное ограничение: From baseline (Day -1) to Day 8 for treatment period 1; from Day 8 to Day 20 for treatment period 2
|
comparing the apparent volume of distribution (Vd/F) by treatment period using descriptive statistics
|
From baseline (Day -1) to Day 8 for treatment period 1; from Day 8 to Day 20 for treatment period 2
|
|
Additional pharmacokinetic parameters: tmax
Временное ограничение: From baseline (Day -1) to Day 8 for treatment period 1; from Day 8 to Day 20 for treatment period 2
|
Evaluating the Hodges-Lehmann non-parametric estimate of location shift between CHF10196 with pantoprazole (test) and CHF10196 alone (reference) in median time corresponding to maximum plasma when CHF10196 administered alone and when administered with pantoprazole concentration (tmax)
|
From baseline (Day -1) to Day 8 for treatment period 1; from Day 8 to Day 20 for treatment period 2
|
Соавторы и исследователи
Спонсор
Следователи
- Главный следователь: Benjamen Monaghan, Fortrea Clinical Research Unit (CRU)
Даты записи исследования
Изучение основных дат
Начало исследования (Оцененный)
Первичное завершение (Оцененный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Дополнительные соответствующие термины MeSH
Другие идентификационные номера исследования
- CLI-10196AA1-05
- 1014440 (Другой идентификатор: IRAS)
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Описание плана IPD
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .